COVID-19 Vaccine : A Review


  • Anggun Elidya
  • Ghalib Nasser Medical Faculty, Lampung University
  • Innou Dhanu
  • Rani Himayani
  • Helmi Ismunandar



COVID19, Imunisasi, Pencegahan


Corona Virus Disease 19 (COVID-19) is a virus that emerged at the end of 2019 which is known to have originated of Wuhan which is the capital of Hubei Province, China. Based on data from the World Health Organization (WHO) until January 31, 2021, 235 countries were infected with COVID-19 and 103 million sufferers worldwide and the death rate reached 2,220,000 with symptoms include high fever, difficulty breathing and coughing, and recognition of these symptoms takes 2 to 14 days after infection. Prevention of COVID-19 can be stopped by early detection, isolation and vaccine administration. The mRNA vaccine is an mRNA encoding antigen that is translated in the host's cellular machine by vaccination. This type of vaccine has a self-amplifying genomic structure that causes extreme RNA replication in the cytosol, such as the example of Pfizer BioTech with the name BNT162 (3 LNP-mRNAs) entering its third phase. Deactivated Virus-Based Vaccine (PiCoVacc) is the development of a conventional vaccine starting with in-vitro neutralization and isolating strands of the SARS-CoV-2 virus. This type of vaccine is the SARS-CoV-2 vaccine (inactivated) which has been distributed to several countries such as Turkey, Brazil and Indonesia by administering two times (0 14) intramuscularly (0.5cc). Subunit vaccines are vaccines that include one or more antigens that can stimulate the host immune system. The DNA vaccine is a vaccine consisting of a plasmid DNA molecule encoding one or more antigens and a SARS-CoV-2 (Ad5-nCoV) Adenovirus Type-5 Vector-Based Vaccine which uses the recombinant adenovirus type 5 (Ad5) vector through spike glycoproteins from the Covid strand -19.


WHO. Prevalence of COVID-19 on December. Geneva: WHO; 2020.

Nadeem, S. Coronavirus COVID-19 : Available Free Literature Provided By Various Companies , Journals and Organizations Around the Literature Provided By Various Companies, Journals and Organizations Around the World. Journal of Ongoing Chemical Research. 2020; 5(1):7-13.

Sohrabi, C. et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)’, International Journal of Surgery. Elsevier. 2020. 76(February), pp. 71– 76. doi: 10.1016/j.ijsu.2020.02.034

Corum, J., Denise G., dan Carl Z. Corona Virus Tracker”[internet]. New York : The New York Times; 2020 [disitasi tanggal 10 Mei 2021]. Tersedia dari :

Wang, F., Richard M. K., dan George B. S. An Evidence Based Perspective on mRNASARS-CoV-2 Vaccine Development. Medical Science Monitor. 2020;26:1-8.

Koesnoe. Teknis Pemberian Vaksin Sinovac. PAPDI: Jakarta; 2020.

Gao, Q., Linlin B., Haiyan M., Lin W., Kangwei X., Minnan Y., dkk. Rapid Development of an Inactivated Vaccine Candidate for SARS-CoV-2. Science. 2020; 1-10.

Prompetchara, E., Ketloy, C. and Palaga, T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic’, Asian Pacific journal of allergy and immunology. 2020;38(1): pp. 1–9. doi: 10.12932/AP-200220-0772

Robson, B. Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus’, Computers in Biology and Medicine. Elsevier Ltd. 2020; p. 103670. doi: 10.1016/j.compbiomed.2020.103670.

Zhu, F.-C., Yu-Hua L., Xu-Hua G., Li-Hua H., Wen-Juan W., Jing-Xin L., dan Wei C. Safety, Tolerability, and Immunogenicity of Recombinant Adenovirus Type-5 Vektored COVID-19 Vaccine: A Dose-escalation, Open-label, Non-rendomised, First-inhuman Trial. Elsevier Ltd. 2020:1-10.

Zhang, L. and Liu, Y. Potential interventions for novel coronavirus in China: A systematic review’, Journal of Medical Virology. 2020; 92(5): 479–490. doi: 10.1002/jmv.25707

Park, T. et al. Spike protein binding prediction with neutralizing antibodies of SARS-CoV-2’, bioRxiv. 2020;p. 2020.02.22.951178. doi: 10.1101/2020.02.22.951178



How to Cite

Anggun Elidya, Nasser, G., Innou Dhanu, Rani Himayani, & Helmi Ismunandar. (2021). COVID-19 Vaccine : A Review. Medical Profession Journal of Lampung, 11(1), 141-144.




Most read articles by the same author(s)

1 2 3 > >>